This ‘Liver Fibrosis- Epidemiology Forecast-2032' report delivers an in-depth understanding of the Liver Fibrosis, historical and forecasted epidemiology as well as the Liver Fibrosis trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Regardless of the etiology, liver fibrosis is characterized by common molecular mechanisms such as hepatocyte death, chronic inflammation with cytokine release, activation of HSCs, and disruption of the epithelial or endothelial barrier.
Liver Fibrosis Disease Understanding
Liver fibrosis results in the accumulation of extracellular matrix (ECM) proteins, mostly collagens Type I and Type III, followed by the formation of fibrous scar, which can ultimately compromise normal liver function. The main causes of liver fibrosis include alcohol abuse, chronic HCV infection, Non-alcoholic fatty liver disease, and NASH (Fatty Liver not due to alcohol use).Regardless of the etiology, liver fibrosis is characterized by common molecular mechanisms such as hepatocyte death, chronic inflammation with cytokine release, activation of HSCs, and disruption of the epithelial or endothelial barrier.
Liver Fibrosis Diagnosis
Fibrosis is a precursor to cirrhosis, and establishing the severity of liver fibrosis helps predict liver-related morbidity and mortality and the emergence of complications of portal hypertension. Noninvasive methods to estimate hepatic fibrosis are commonly used in clinical practice as a safer, more accessible, and less costly strategy than liver biopsy for stratifying persons according to risk. These methods include indirect biomarkers, direct biomarkers, and elastography. If a combination of noninvasive methods provides a clear-cut assessment of hepatic fibrosis, further assessment with liver biopsy is generally not needed. Although liver biopsy with histologic analysis has long been considered the gold standard evaluation of hepatic fibrosis, it is now infrequently used to evaluate liver fibrosis in persons with chronic HCV. In the current era, the optimal approach to fibrosis assessment is to use noninvasive serum markers/tests in conjunction with transient elastography.Liver Fibrosis Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Liver Fibrosis, Severity-specific Diagnosed Cases of Non Alcoholic Steatohepatitis (NASH), Total Diagnosed Prevalent cases of Liver Fibrosis in NASH, in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan, from 2019 to 2032.Liver Fibrosis Detailed Epidemiology Segmentation
- In the assessment done by the publisher, the estimated total diagnosed prevalent cases of Liver Fibrosis in the 7MM were 19,126,579 in 2021.
- The highest total diagnosed prevalent cases of Liver Fibrosis were accounted by the US in 2021 (9,488,135 cases), which are expected to show a rise in the future.
- Among the European countries, Germany had the highest diagnosed prevalent cases of Liver Fibrosis with 1,641,162 cases, followed by Italy, which had prevalent population of 1,532,651 in 2021. On the other hand, Spain had the lowest prevalent population (1,307,582 cases).
- Japan had 2,299,149 total diagnosed prevalent cases of Liver Fibrosis in 2021, accounting for approximately 12% in 7MM.
Scope of the Report
- The report covers the descriptive overview of Liver Fibrosis, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
- The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan.
- The report assesses the disease risk and burden of Liver Fibrosis.
- The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
Report Highlights
- 11-Year Forecast of Liver Fibrosis
- 7MM Coverage
- Total Diagnosed Prevalent Cases of Liver Fibrosis
- Severity-specific Diagnosed Prevalent Cases of NASH
- Diagnosed Prevalent Cases of NASH-specific Liver Fibrosis
Key Questions Answered
- What are the disease risk and burden of Liver Fibrosis?
- What is the historical Liver Fibrosis patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
- What would be the forecasted patient pool of Liver Fibrosis at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Liver Fibrosis?
- Out of the above-mentioned countries, which country would have the highest prevalent population of Liver Fibrosis during the forecast period (2022-2032)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?
Reasons to Buy
The Liver Fibrosis report will allow the user to -- Develop business strategies by understanding the trends shaping and driving the 7MM+ Liver Fibrosis epidemiology forecast.
- The Liver Fibrosis epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
- The Liver Fibrosis epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.
Key Assessments
- Patient Segmentation
- Patient Segmentation based on Severity-specific
- Patient Segmentation based on NASH-specific
Geographies Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Table of Contents
1. Key Insights2. Report Introduction
3. Liver Fibrosis Epidemiology Overview at a Glance
3.1. Patient Share (%) Distribution of Liver Fibrosis in 2019
3.2. Patient Share (%) Distribution of Liver Fibrosis in 2032
4. Executive Summary of Liver Fibrosis
5. Disease Background and Overview: Liver Fibrosis
5.1. Introduction of Liver Fibrosis
5.2. Fibrogenesis in Liver Fibrosis
5.3. Etiology of Liver Fibrosis
5.3.1. Metabolic disorders: Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
5.3.2. Genetic disorders
5.3.3. Alcohol
5.3.4. Drugs
5.3.5. Cholestasis
5.3.6. Viral hepatitis
5.3.7. Parasitic infections
5.3.8. Cryptogenic causes
5.4. Pathophysiology of Liver Fibrosis
5.4.1. Cell types in liver fibrosis
5.5. Diagnostic Approach for Liver Fibrosis
5.5.1. General approach to evaluate liver fibrosis
5.5.2. Liver biopsy and histologic assessment of the liver
5.5.3. Classification of liver histology
5.5.4. Indirect markers of fibrosis
5.5.5. Direct markers of fibrosis
5.5.6. Radiologic Modalities to Estimate Fibrosis
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Methodology of Epidemiology
6.3. Assumptions and Rationale: 7MM
6.3.1. United States
6.3.2. EU-5 Countries
6.3.3. Japan
6.4. Total Diagnosed Prevalent cases of Liver Fibrosis in the 7MM
6.5. The United States
6.5.1. Total diagnosed prevalent cases of Liver fibrosis in the United States
6.5.2. Severity-specific Diagnosed cases of Non Alcoholic Steatohepatitis (NASH) in the United States
6.5.3. Total Diagnosed Prevalent cases of Liver fibrosis in NASH in the United States
6.6. Major Five European Countries
6.6.1. Total diagnosed prevalent cases of Liver fibrosis in the EU-5
6.6.2. Severity-specific Diagnosed cases of Non Alcoholic Steatohepatitis (NASH) in the EU-5
6.6.3. Total Diagnosed Prevalent cases of Liver fibrosis in NASH in the EU-5
6.7. Japan
6.7.1. Total diagnosed prevalent cases of Liver fibrosis in Japan
6.7.2. Severity-specific Diagnosed cases of Non Alcoholic Steatohepatitis (NASH) in Japan
6.7.3. Total Diagnosed Prevalent cases of Liver fibrosis in NASH in Japan
7. Patient Journey
8. KOL Views
9. Appendix
9.1. Bibliography
9.2. List of Abbreviations
10. Report Methodology
11. Publisher Capabilities
12. Disclaimer
13. About the Publisher
List of Tables
Table 1 : Summary of Liver Fibrosis Epidemiology (2019-2032)
Table 2 : Total Diagnosed Prevalent cases of Liver Fibrosis in the 7MM, in ‘000’ (2019-2032)
Table 3 : Total Diagnosed Prevalent Cases of Liver Fibrosis in the US, in ‘000’ (2019-2032)
Table 4 : Severity-specific Diagnosed cases of Non Alcoholic Steatohepatitis (NASH) in the US, in ‘000’ (2019-2032)
Table 5 : Total Diagnosed Prevalent Cases of Liver Fibrosis in NASH in the US, in ‘000’ (2019-2032)
Table 6 : Total Diagnosed Prevalent Cases of Liver Fibrosis in the EU-5, in ‘000’ (2019-2032)
Table 7 : Severity-specific Diagnosed cases of Non Alcoholic Steatohepatitis (NASH) in the EU-5, in ‘000’ (2019-2032)
Table 8 : Severity-specific Diagnosed cases of Non Alcoholic Steatohepatitis (NASH) in Germany, in ‘000’ (2019-2032)
Table 9 : Severity-specific Diagnosed cases of Non Alcoholic Steatohepatitis (NASH) in France, in ‘000’ (2019-2032)
Table 10 : Severity-specific Diagnosed cases of Non Alcoholic Steatohepatitis (NASH) in Italy, in ‘000’ (2019-2032)
Table 11 : Severity-specific Diagnosed cases of Non Alcoholic Steatohepatitis (NASH) in Spain, in ‘000’ (2019-2032)
Table 12 : Severity-specific Diagnosed cases of Non Alcoholic Steatohepatitis (NASH) in the UK, in ‘000’ (2019-2032)
Table 13 : Total Diagnosed Prevalent cases of Liver Fibrosis in NASH in EU-5, in ‘000’ (2019-2032)
Table 14 : Total Diagnosed Prevalent cases of Liver Fibrosis in Japan, in ‘000’ (2019-2032)
Table 15 : Severity-specific Diagnosed cases of Non Alcoholic Steatohepatitis (NASH) in Japan, in ‘000’ (2019-2032)
Table 16 : Total Diagnosed Prevalent cases of Liver fibrosis in NASH in Japan, in ‘000’ (2019-2032)
Table 17 : List of abbreviationsList of Figures
Figure 1: Liver Architecture in Healthy Liver and Fibrosis. (A) Normal liver (B) Injury to hepatocytes due to any of Several Causes, Such as Alcohol, Drug, Genetic Predisposition, etc., Activates the Wound Healing Fibrogenic Response
Figure 2: Drivers Predisposing the Liver to Fibrosis
Figure 3: The TGF-β Signaling Pathway in Hepatic Stellate Cells
Figure 4: Summary of Important Pathways in the Progression of NAFLD to NASH
Figure 5: Alcohol Metabolism in the Liver
Figure 6: Metabolism of Drugs and Other Xenobiotics in the Liver
Figure 7: Pathophysiology of Liver Fibrosis
Figure 8: Aspartate Aminotransferase-to-Platelet-Ratio Index (APRI)
Figure 9: The Fib4 Represents an Easy-to-use Test for Predicting Severe Hepatic Fibrosis or Cirrhosis.
Figure 10: The FibroIndex is a Complicated Calculation That Requires a Platelet Count, Aspartate Aminotransferase (AST) Level, and Gamma Globulin Level.
Figure 11: The Forns Index Incorporates Easy-to-obtain Parameters but Requires a Highly Complicated Calculation
Figure 12: HepaScore (FibroScore)
Figure 13: Castera Transient Elastography Cutoffs Correlating With Metavir Fibrosis
Figure 14: Castera Transient Elastography Cutoffs Correlating With Metavir Fibrosis
Figure 15: Ziols Transient Elastography Cutoffs Correlating with Metavir Fibrosis
Figure 16: Ziols Transient Elastography Cutoffs Correlating with Metavir Fibrosis
Figure 17: Castera and Ziol Cut-offs for Metavir F3 Fibrosis Score
Figure 18: Total Diagnosed Prevalent Cases of Liver Fibrosis in the 7MM, in ‘000’ (2019-2032)
Figure 19: Total Diagnosed Prevalent Cases of Liver Fibrosis in the US, in ‘000’ (2019-2032)
Figure 20: Severity-specific Diagnosed cases of Non Alcoholic Steatohepatitis (NASH) in the US, in ‘000’ (2019-2032)
Figure 21: Total Diagnosed Prevalent cases of Liver fibrosis in NASH in the US, in ‘000’ (2019-2032)
Figure 22: Total Diagnosed Prevalent Cases of Liver Fibrosis in the EU-5, in ‘000’ (2019-2032)
Figure 23: Severity-specific Diagnosed cases of Non Alcoholic Steatohepatitis (NASH) in the EU-5, in ‘000’ (2019-2032)
Figure 24: Total Diagnosed Prevalent cases of Liver fibrosis in NASH in the EU-5, in ‘000’ (2019-2032)
Figure 25: Total Diagnosed Prevalent Cases of Liver Fibrosis in Japan, in ‘000’ (2019-2032)
Figure 26: Severity-specific Diagnosed cases of Non Alcoholic Steatohepatitis (NASH) in Japan, in ‘000’ (2019-2032)
Figure 27: Total Diagnosed Prevalent cases of Liver fibrosis in NASH in Japan, in ‘000’ (2019-2032)
Figure 28: Patient Journey
